文献速递乳腺癌

恩扎卢胺治疗雄激素受体阳性三阴性乳腺癌的II期研究

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
PubMed 文献 · J Clin Oncol · 2018-01-26

该II期研究评估恩扎卢胺在局部晚期或转移性雄激素受体(AR)阳性三阴性乳腺癌(TNBC)中的抗肿瘤活性与安全性,主要终点为16周临床获益率(CBR)。全组118例中可评估78例,16周CBR在ITT人群为25%、可评估亚组为33%,中位无进展生存期分别为2.9个月和3.3个月,疲乏是唯一发生率>2%的治疗相关≥3级不良事件。

要点

  • 恩扎卢胺在AR阳性晚期TNBC中显示出临床活性且耐受性良好。
  • 16周CBR在ITT人群为25%,在核AR≥10%的可评估亚组为33%。
  • 中位无进展生存期ITT人群2.9个月,可评估亚组3.3个月。

核心结论

  • 恩扎卢胺在晚期AR阳性TNBC患者中显示出临床活性且耐受性良好。
  • 研究支持在晚期TNBC中进一步开发恩扎卢胺。

研究设计与样本

  • II期研究评估恩扎卢胺治疗局部晚期或转移性AR阳性TNBC的抗肿瘤活性与安全性。
  • 入组118例患者,其中78例为可评估亚组(至少一次基线后评估且肿瘤核AR≥10%)。
  • 患者每日一次口服恩扎卢胺160 mg直至疾病进展。
  • 主要终点为16周临床获益率(CBR),次要终点包括24周CBR、无进展生存期和安全性。

主要发现

  • 16周CBR在ITT人群为25%(95%CI 17%至33%),在可评估亚组为33%(95%CI 23%至45%)。
  • 中位无进展生存期在ITT人群为2.9个月(95%CI 1.9至3.7个月),在可评估亚组为3.3个月(95%CI 1.9至4.1个月)。
  • 中位总生存期在ITT人群为12.7个月(95%CI 8.5个月至未达到),在可评估亚组为17.6个月(95%CI 11.6个月至未达到)。
  • 疲乏是唯一发生率>2%的治疗相关≥3级不良事件。

关键数值与推荐

  • AR阳性定义为核AR染色>0%(采用为乳腺癌优化的免疫组化检测)。
  • 可评估亚组定义为至少一次基线后评估且肿瘤核AR≥10%。

临床怎么用

  • 对晚期AR阳性TNBC患者,恩扎卢胺160 mg每日一次可作为具有临床活性的治疗选择。
  • 治疗期间需关注疲乏等不良事件,其安全谱与已知特征一致。

局限性

  • 本研究为II期单臂研究,样本量有限(入组118例,可评估78例)。
  • AR阳性定义采用>0%核染色,可评估亚组采用≥10%核AR,阈值选择可能影响结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor. This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-positive TNBC. Patients and Methods Tumors were tested for AR with an immunohistochemistry assay optimized for breast cancer; nuclear AR staining > 0% was considered positive. Patients received enzalutamide 160 mg once per day until disease progression. The primary end point was clinical benefit rate (CBR) at 16 weeks. Secondary end points included CBR at 24 weeks, progression-free survival, and safety. End points were analyzed in all enrolled patients (the intent-to-treat [ITT] population) and in patients with one or more postbaseline assessment whose tumor expressed ≥ 10% nuclear AR (the evaluable subgroup). Results Of 118 patients enrolled, 78 were evaluable. CBR at 16 weeks was 25% (95% CI, 17% to 33%) in the ITT population and 33% (95% CI, 23% to 45%) in the evaluable subgroup. Median progression-free survival was 2.9 months (95% CI, 1.9 to 3.7 months) in the ITT population and 3.3 months (95% CI, 1.9 to 4.1 months) in the evaluable subgroup. Median overall survival was 12.7 months (95% CI, 8.5 months to not yet reached) in the ITT population and 17.6 months (95% CI, 11.6 months to not yet reached) in the evaluable subgroup. Fatigue was the only treatment-related grade 3 or higher adverse event with an incidence of > 2%. Conclusion Enzalutamide demonstrated clinical activity and was well tolerated in patients with advanced AR-positive TNBC. Adverse events related to enzalutamide were consistent with its known safety profile. This study supports additional development of enzalutamide in advanced TNBC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Traina TA, Miller K, Yardley DA, et al. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol. 2018. PMID: 29373071. doi:10.1200/JCO.2016.71.3495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。